Geraldine Pannu, a member of the board of directors at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), reported a direct purchase of 2,072 shares of the company's common stock at a price of $2.535 per share, for a total consideration of $5,252. The trade, recorded on a Form 4 filed with the Securities and Exchange Commission, took place on March 31, 2026.
Following the transaction, Pannu's direct ownership in Processa increased to 2,188 shares. At the time of reporting, the stock is trading at $2.60, reflecting a 9.78% gain over the last week, while the company’s share price remains down 75% over the past year.
Processa Pharmaceuticals carries a market capitalization of $6.97 million. According to an InvestingPro analysis cited in company reporting, the firm's balance sheet shows more cash than debt, and the analysis provides 11 additional ProTips for investors in PCSA.
Clinical update
On the clinical front, Processa has completed enrollment and dosing of 20 patients for an interim analysis in its Phase 2 study evaluating NGC-Cap in advanced or metastatic breast cancer. The regimen being studied combines PCS6422 and capecitabine and is being compared against standard capecitabine monotherapy.
The trial cohort consists of patients who have received at least one prior line of therapy; the median number of previous treatments among participants ranges from two to three regimens. Completion of enrollment and dosing for the interim analysis represents a key operational milestone for the company’s ongoing research program.
Implications and context
- This insider purchase is a direct acquisition disclosed by a company director via SEC filing.
- Market performance is mixed in the short term with weekly gains but a significant year-over-year decline.
- Clinical progress includes completion of dosing for an interim analysis in a Phase 2 breast cancer study.
Note on additional resources
The company’s profile and balance-sheet characterization referenced the InvestingPro analysis, which includes the stated ProTips for PCSA investors.